Damora Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.18B
- P/E (TTM)
- 4.8
- Dividend yield
- 0.00%
About Damora Therapeutics
Pharmaceutical Preparations, SIC 2834
Damora Therapeutics, Inc. is a preclinical-stage biopharmaceutical company focused on discovering and developing therapies for hematologic disorders. The company's pipeline centers on treatments for myeloproliferative neoplasms, which are chronic bone marrow disorders driven by myeloid cell proliferation. Its primary development programs include DMR-001, DMR-002, and DMR-003, which are monoclonal antibody candidates designed to selectively target mutant calreticulin. These investigational therapies aim to treat patients diagnosed with essential thrombocythemia and myelofibrosis.
The company operates in the United States and conducts its research and development programs through collaborative licensing arrangements. Its lead therapeutic candidates remain in preclinical development, with regulatory filings planned across multiple target indications. Damora Therapeutics maintains its principal executive offices in Waltham, Massachusetts.
Summary of the business section of Damora Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Damora Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 221 Crescent Street, Building 23, Suite 105 02453
- Phone
- (781) 281-9020
- Website
- damoratx.com
- Employees
- 7, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EY Godkendt Revisionspartnerselskab, Copenhagen, Denmark
Stock & identifiers
- Ticker
- DMRA
- Exchange
- Nasdaq
- IPO date
- Oct 30, 2020
- Shares outstanding
- 62M, Aug 7, 2026
- Public float
- $4.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Aug 30, 2024; 1-for-25 reverse, Aug 29, 2024
- SEC CIK
- 1800315
- CUSIP
- 36322Q206
- ISIN
- US36322Q2066
- EIN
- 37-1957007
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jennifer Jarrett | Director, President and CEO | 512,500 |
| Hans T. Schambye | Chief Executive Officer, Director | 4,682 |
| Garrett Winslow | General Counsel | 2,289 |
| Brian Burkavage | SVP, Finance | – |
| Sherwin Sattarzadeh | Chief Operating Officer | 190,376 |
| L. Becker Hewes | Chief Medical Officer | 264,629 |
| Lori Firmani | Chief Financial Officer | 931 |
| Matthew Kronmiller | EVP Strategy and CBO | – |
| Andrew Cheng | Director | – |
| Healthcare Fund II L.P. Fairmount | Director | 8,713,000 |
| Cameron Turtle | Director | – |
| Christopher W. Cain | Director | – |
| Peter Evan Harwin | Director | – |
| Funds Management LLC Fairmount | Director | – |
| Julianne Bruno | Director | 137,032 |
| Healthcare Co-Invest V. L.P. Fairmount | Director | – |
| Michael Landsittel | Director | – |
| David Shapiro | Director | – |
| Jayson Donald Alexander Dallas | Director | – |
| Amit Munshi | Director | 4,793 |
| Anne Prener | Director | – |
| Carl Goldfischer | Director | 1,049,055 |
| Amy B. Wechsler | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Hans T. Schambye, M.D., Ph.D. | $1.30M | $2.13M | $708.98K | $128 | – |
| FY2024 Hans T. Schambye, M.D., Ph.D. | $1.43M | $1.23M | $759.67K | $26 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had seven full-time employees, including one who holds a Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 20, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 10, 2026 | Name change | Name changed from Galecto, Inc. to Damora Therapeutics, Inc. |
| Nov 10, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 7, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 2, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 30, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 23, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |